Published in Genet Test Mol Biomarkers on January 22, 2011
An exploration of genetic counselors' needs and experiences with prenatal chromosomal microarray testing. J Genet Couns (2014) 1.63
"Nothing is absolute in life": understanding uncertainty in the context of psychiatric genetic counseling from the perspective of those with serious mental illness. J Genet Couns (2013) 0.90
Paternalism or partnership? Patients have grown up-and there's no going back. BMJ (1999) 10.30
The pathology of familial breast cancer: predictive value of immunohistochemical markers estrogen receptor, progesterone receptor, HER-2, and p53 in patients with mutations in BRCA1 and BRCA2. J Clin Oncol (2002) 6.16
The effects of problem-based learning during medical school on physician competency: a systematic review. CMAJ (2008) 3.86
Genetic predisposition to breast cancer: past, present, and future. Annu Rev Genomics Hum Genet (2008) 3.40
Do the print media "hype" genetic research? A comparison of newspaper stories and peer-reviewed research papers. CMAJ (2004) 3.08
Contralateral breast cancer risk in BRCA1 and BRCA2 mutation carriers. J Clin Oncol (2009) 2.47
Communicating the uncertainty of harms and benefits of medical interventions. Med Decis Making (2007) 2.34
Medical knowledge overload: a disturbing trend for physicians. Health Care Manage Rev (1997) 2.33
Hereditary breast cancer: new genetic developments, new therapeutic avenues. Hum Genet (2008) 1.96
Measuring physicians' tolerance for ambiguity and its relationship to their reported practices regarding genetic testing. Med Care (1993) 1.71
Modifiers of risk of hereditary breast cancer. Oncogene (2006) 1.34
Shared decision making and non-directiveness in genetic counselling. J Med Genet (2000) 1.31
Biofantasies: genetics and medicine in the print news media. Soc Sci Med (2001) 1.30
Survival in prospectively ascertained familial breast cancer: analysis of a series stratified by tumour characteristics, BRCA mutations and oophorectomy. Int J Cancer (2002) 1.26
What does my doctor think? Preferences for knowing the doctor's opinion among women considering clinical testing for BRCA1/2 mutations. Genet Test (2002) 1.25
Tolerance for uncertainty and perceived risk among women receiving uninformative BRCA1/2 test results. Am J Med Genet C Semin Med Genet (2006) 1.21
Decision making and quality of life in the treatment of cancer: a review. Support Care Cancer (2008) 1.19
Translating evidence-based information into effective risk communication: current challenges and opportunities. J Lab Clin Med (2005) 1.19
Clinical characteristics affect the impact of an uninformative DNA test result: the course of worry and distress experienced by women who apply for genetic testing for breast cancer. J Clin Oncol (2006) 1.15
Peer-support in coping with medical uncertainty: discussion of oophorectomy and hormone replacement therapy on a web-based message board. Psychooncology (2007) 1.11
The converged experience of risk and disease. Milbank Q (2009) 1.08
Low penetrance genes associated with increased risk for breast cancer. Eur J Cancer (2000) 1.05
BRCA1 and BRCA2 as ovarian cancer susceptibility genes. Carcinogenesis (2005) 1.02
Patient empowerment in clinical genetics services. J Health Psychol (2008) 1.01
The pathology of inherited breast cancer. Pathology (2002) 1.00
Is no news good news? Inconclusive genetic test results in BRCA1 and BRCA2 from patients and professionals' perspectives. Hered Cancer Clin Pract (2010) 0.94
Negotiating the diagnostic uncertainty of contested illnesses: physician practices and paradigms. Health (London) (2008) 0.92
Patient empowerment and the dilemmas of late-modern medicalisation. Lancet (2007) 0.91
Nuance, complexity, and context: qualitative methods in genetic counseling research. J Genet Couns (1997) 0.91
Barriers and enablers of health promotion, prevention and early intervention in primary care: evidence to inform the Australian national dementia strategy. Australas J Ageing (2009) 0.79
Low-penetrance susceptibility to breast cancer due to CHEK2(*)1100delC in noncarriers of BRCA1 or BRCA2 mutations. Nat Genet (2002) 9.71
Association of risk-reducing surgery in BRCA1 or BRCA2 mutation carriers with cancer risk and mortality. JAMA (2010) 8.93
DNA-Repair Defects and Olaparib in Metastatic Prostate Cancer. N Engl J Med (2015) 5.39
Association between BRCA1 and BRCA2 mutations and survival in women with invasive epithelial ovarian cancer. JAMA (2012) 3.85
MRI breast screening in high-risk women: cancer detection and survival analysis. Breast Cancer Res Treat (2014) 3.46
Common breast cancer-predisposition alleles are associated with breast cancer risk in BRCA1 and BRCA2 mutation carriers. Am J Hum Genet (2008) 3.41
"BRCAness" syndrome in ovarian cancer: a case-control study describing the clinical features and outcome of patients with epithelial ovarian cancer associated with BRCA1 and BRCA2 mutations. J Clin Oncol (2008) 3.25
Mortality after bilateral salpingo-oophorectomy in BRCA1 and BRCA2 mutation carriers: a prospective cohort study. Lancet Oncol (2006) 3.02
Germline BRCA mutations are associated with higher risk of nodal involvement, distant metastasis, and poor survival outcomes in prostate cancer. J Clin Oncol (2013) 2.71
Effect of short-term hormone replacement therapy on breast cancer risk reduction after bilateral prophylactic oophorectomy in BRCA1 and BRCA2 mutation carriers: the PROSE Study Group. J Clin Oncol (2005) 2.70
Two percent of men with early-onset prostate cancer harbor germline mutations in the BRCA2 gene. Am J Hum Genet (2002) 2.57
Common variants in LSP1, 2q35 and 8q24 and breast cancer risk for BRCA1 and BRCA2 mutation carriers. Hum Mol Genet (2009) 2.13
Transcription factor E2F3 overexpressed in prostate cancer independently predicts clinical outcome. Oncogene (2004) 1.90
The role of genetic markers in the management of prostate cancer. Eur Urol (2012) 1.88
Integration of ERG gene mapping and gene-expression profiling identifies distinct categories of human prostate cancer. BJU Int (2008) 1.88
Functional significance and clinical phenotype of nontruncating mismatch repair variants of MLH1. Gastroenterology (2005) 1.70
Hyperplastic polyposis syndrome: phenotypic presentations and the role of MBD4 and MYH. Gastroenterology (2006) 1.66
Validation of genome-wide prostate cancer associations in men of African descent. Cancer Epidemiol Biomarkers Prev (2010) 1.62
Identification of nine new susceptibility loci for testicular cancer, including variants near DAZL and PRDM14. Nat Genet (2013) 1.58
Detection of TMPRSS2-ERG translocations in human prostate cancer by expression profiling using GeneChip Human Exon 1.0 ST arrays. J Mol Diagn (2007) 1.55
Sexual activity and prostate cancer risk in men diagnosed at a younger age. BJU Int (2008) 1.43
We are talking, but are they listening? Communication patterns in families with a history of breast/ovarian cancer (HBOC). Psychooncology (2004) 1.38
Global patterns of prostate cancer incidence, aggressiveness, and mortality in men of african descent. Prostate Cancer (2013) 1.37
Reproductive and hormonal factors, and ovarian cancer risk for BRCA1 and BRCA2 mutation carriers: results from the International BRCA1/2 Carrier Cohort Study. Cancer Epidemiol Biomarkers Prev (2009) 1.25
Interplay between BRCA1 and RHAMM regulates epithelial apicobasal polarization and may influence risk of breast cancer. PLoS Biol (2011) 1.12
Overexpression of RAD51 occurs in aggressive prostatic cancer. Histopathology (2009) 1.05
BRCA1/2 predictive testing: a study of uptake in two centres. Eur J Hum Genet (2004) 1.02
Bilateral prophylactic oophorectomy and bilateral prophylactic mastectomy in a prospective cohort of unaffected BRCA1 and BRCA2 mutation carriers. Clin Breast Cancer (2007) 1.01
Association of the variants CASP8 D302H and CASP10 V410I with breast and ovarian cancer risk in BRCA1 and BRCA2 mutation carriers. Cancer Epidemiol Biomarkers Prev (2010) 1.01
The rs10993994 risk allele for prostate cancer results in clinically relevant changes in microseminoprotein-beta expression in tissue and urine. PLoS One (2010) 1.01
The role of BRCA1 and BRCA2 in prostate cancer. Asian J Androl (2012) 1.00
Family stories and the use of heuristics: women from suspected hereditary breast and ovarian cancer (HBOC) families. Sociol Health Illn (2003) 1.00
The potential value of microseminoprotein-beta as a prostate cancer biomarker and therapeutic target. Prostate (2010) 0.99
Attitudes to reproductive genetic testing in women who had a positive BRCA test before having children: a qualitative analysis. Eur J Hum Genet (2011) 0.99
Rare germ line CHEK2 variants identified in breast cancer families encode proteins that show impaired activation. Cancer Res (2006) 0.96
Acute chemotherapy-related toxicity is not increased in BRCA1 and BRCA2 mutation carriers treated for breast cancer in the United Kingdom. Clin Cancer Res (2006) 0.94
Occult ovarian cancers identified at risk-reducing salpingo-oophorectomy in a prospective cohort of BRCA1/2 mutation carriers. Breast Cancer Res Treat (2010) 0.93
Breast and ovarian cancer risk and risk reduction in Jewish BRCA1/2 mutation carriers. J Clin Oncol (2012) 0.91
p53 therapy in a patient with Li-Fraumeni syndrome. Mol Cancer Ther (2007) 0.91
Genetic testing for breast and ovarian cancer predisposition: cancer burden and responsibility. J Health Psychol (2002) 0.90
Dietary fat and early-onset prostate cancer risk. Br J Nutr (2010) 0.90
Heterogeneous genetic background of the association of pheochromocytoma/paraganglioma and pituitary adenoma: results from a large patient cohort. J Clin Endocrinol Metab (2014) 0.90
Relationship between glutathione S-transferase M1, T1, and P1 polymorphisms and chronic lymphocytic leukemia. Blood (2002) 0.89
Unusual presentation of Lynch Syndrome. Hered Cancer Clin Pract (2009) 0.87
Late toxicity is not increased in BRCA1/BRCA2 mutation carriers undergoing breast radiotherapy in the United Kingdom. Clin Cancer Res (2006) 0.86
A multicenter study of cancer incidence in CHEK2 1100delC mutation carriers. Cancer Epidemiol Biomarkers Prev (2006) 0.86
Predictive testing of eighteen year olds: counseling challenges. J Genet Couns (2006) 0.85
No evidence that GATA3 rs570613 SNP modifies breast cancer risk. Breast Cancer Res Treat (2008) 0.84
Outcome of early detection and radiotherapy for occult spinal cord compression. Radiother Oncol (2007) 0.84
Lymphocyte radiosensitivity in BRCA1 and BRCA2 mutation carriers and implications for breast cancer susceptibility. Int J Cancer (2007) 0.84
"Social separation" among women under 40 years of age diagnosed with breast cancer and carrying a BRCA1 or BRCA2 mutation. J Genet Couns (2006) 0.83
Optimal age to start preventive measures in women with BRCA1/2 mutations or high familial breast cancer risk. Int J Cancer (2013) 0.82
Use of risk-reducing surgeries in a prospective cohort of 1,499 BRCA1 and BRCA2 mutation carriers. Breast Cancer Res Treat (2014) 0.81
Cancer genetics: the importance of obtaining a family history. Nurs Times (2006) 0.81
Eligibility for magnetic resonance imaging screening in the United Kingdom: effect of strict selection criteria and anonymous DNA testing on breast cancer incidence in the MARIBS Study. Cancer Epidemiol Biomarkers Prev (2009) 0.80
Breast cancer risk and 6q22.33: combined results from Breast Cancer Association Consortium and Consortium of Investigators on Modifiers of BRCA1/2. PLoS One (2012) 0.80
BRCA1/BRCA2 mutation status and analysis of cancer family history in participants of the Royal Marsden Hospital tamoxifen chemoprevention trial. Cancer Lett (2006) 0.80
Translating genetic risk factors for prostate cancer to the clinic: 2013 and beyond. Future Oncol (2014) 0.79
Exploring the link between MORF4L1 and risk of breast cancer. Breast Cancer Res (2011) 0.79
Corrigendum: analysis of the genetic phylogeny of multifocal prostate cancer identifies multiple independent clonal expansions in neoplastic and morphologically normal prostate tissue. Nat Genet (2015) 0.79
Biallelic PMS2 mutations and a distinctive childhood cancer syndrome. J Pediatr Hematol Oncol (2008) 0.78
Proteomic analysis of nipple aspirate fluid throughout the menstrual cycle in healthy pre-menopausal women. Breast Cancer Res Treat (2006) 0.78
Role of Engrailed-2 (EN2) as a prostate cancer detection biomarker in genetically high risk men. Sci Rep (2013) 0.78
Genetic testing for BRCA1: effects of a randomised study of knowledge provision on interest in testing and long term test uptake; implications for the NICE guidelines. Fam Cancer (2008) 0.77
Analysis of Xq27-28 linkage in the international consortium for prostate cancer genetics (ICPCG) families. BMC Med Genet (2012) 0.76
Ductal approaches to assessment and management of women at high risk for developing breast cancer. Breast Cancer Res (2004) 0.76
An assessment of the shared allelic architecture between type II diabetes and prostate cancer. Cancer Epidemiol Biomarkers Prev (2013) 0.76
Developments in Clinical Practice: Follow up Clinic for BRCA Mutation Carriers: a Case Study Highlighting the "Virtual Clinic". Hered Cancer Clin Pract (2004) 0.75
Screening for ovarian cancer in women with varying levels of risk, using annual tests, results in high recall for repeat screening tests. Hered Cancer Clin Pract (2011) 0.75
The clinical genetics of prostate cancer. Hered Cancer Clin Pract (2004) 0.75
Medullary and non-medullary thyroid cancer in a family. Acta Oncol (2004) 0.75
Corrigendum: Frequent somatic transfer of mitochondrial DNA into the nuclear genome of human cancer cells. Genome Res (2016) 0.75
"It's all very well reading the letters in the genome, but it's a long way to being able to write": Men's interpretations of undergoing genetic profiling to determine future risk of prostate cancer. Fam Cancer (2014) 0.75
Baseline and post prophylactic tubal-ovarian surgery CA125 levels in BRCA1 and BRCA2 mutation carriers. Fam Cancer (2014) 0.75